
Your Dose of Cannabis Education

Your Dose of Cannabis Education
Only have a minute but want to Learn something every day™? Sign up to receive Your Dose of Cannabis Education, bringing featured content from our course library right to your inbox each day.
Your Dose of Cannabis Education is based on data from the studies and reviews published in the current peer-reviewed medical journals. Whether you are a healthcare provider, patient, caregiver, an individual working in the healthcare sector, or just a curious person, you can benefit from Your Dose of Cannabis Education.
Wake up every morning and get your dose of unbiased evidence-based cannabis education!

According to a British Medical Journal (BMJ) article, "THC inhibits glutamate and 5-hydroxytryptamine release and increases dopamine secretion. CBD enhances adenosine receptor signaling, and decreases reactive oxygen species, tumour necrosis factor, and T cell proliferation, without the psychoactive effects of THC. The multifaceted analgesic and anti-inflammatory properties of cannabinoids may positively influence the perception of pain across different conditions." (BMJ)
“The major components of the endocannabinoid system in the brain, including functional CB1 receptors and the endocannabinoids 2-AG and AEA, are present around gestational week 19 in humans and likely have a role in critical early behavior processes... This system may also contribute to the proper formation, growth, migration, and wiring of various areas in the developing fetal brain. The expression of the CB1 receptor in the brain also changes throughout human development. Both the expression levels and locations of expression differ greatly between fetal brain development and early life when compared to adult brains.”
The activation of CB2 receptors results in various outcomes, including the inhibition of pro-inflammatory cytokine production and migration of immune cells (neutrophil and macrophages). As a result of these effects, chronic pain may be reduced.
Possibly... A "study explored the use of highly purified Cannabidiol (CBD, Epidiolex) as an add-on therapy for individuals with drug- resistant epilepsy due to Rett Syndrome (RTT) or CDKL5 Deficiency Disorder (CDD). Twenty-seven participants received CBD alongside their usual ASMs [anti-seizure medications]. After a median treatment duration of 14 months, 66.6% experienced fewer seizures, with some showing over 75% reduction. Side effects were generally mild, mainly sleepiness or irritability. Notably, caregivers reported improvements in attention, responsiveness, sleep, and motor function. While results were not statistically significant, they suggest CBD may benefit seizure control and quality of life in RTT and CDD patients.
According to the results of a survey of 145 dermatologists, 91 % of dermatologists were in support of medical cannabis use and 13.8 % have recommended it for a dermatologic condition. Atopic dermatitis (45 %) and psoriasis (40 %) were the most common. The most common form of administration was topical (75 %). The main reasons for not recommending medical cannabis were limited knowledge (56 %) and lack of experience (48 %).
Learn something every day™ in your
feed…
Our courses

CBD in Clinical Care V2

A Nationally Approved CME/CE Medical Marijuana Course V2

Cannabis Essentials CME/CE Bundle
New to TheAnswerPage? There’s lots we’d like to share with you and we don’t want you to miss a thing! Be sure to register today for “Your Dose of Cannabis Education” emails where you’ll gain valuable insights in small doses that fit your schedule and also be provided direct access to the archived daily content.

